Get the Stockscreener App
1.58
5.39%
-0.09
After Hours:
1.56
-0.02
-1.27%
Hoth Therapeutics Inc stock is traded at $1.58, with a volume of 756.01K.
It is down -5.39% in the last 24 hours and down -1.86% over the past month.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).
See More
Previous Close:
$1.67
Open:
$1.67
24h Volume:
756.01K
Relative Volume:
0.71
Market Cap:
$20.95M
Revenue:
-
Net Income/Loss:
$-7.51M
P/E Ratio:
-1.197
EPS:
-1.32
Net Cash Flow:
$-8.02M
1W Performance:
+0.00%
1M Performance:
-1.86%
6M Performance:
+96.40%
1Y Performance:
+112.85%
1-Day Range:
$1.56
$1.7197
1-Week Range:
$1.46
$1.78
52-Week Range:
$0.6506
$3.80
Hoth Therapeutics Inc Stock (HOTH) Company Profile
Name
Hoth Therapeutics Inc
Sector
Industry
Phone
(646)756-2997
Address
1177 AVENUE OF THE AMERICAS, NEW YORK, NY
Compare HOTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOTH
Hoth Therapeutics Inc
|
1.58 | 22.14M | 0 | -7.51M | -8.02M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-19 | Initiated | The Benchmark Company | Speculative Buy |
Hoth Therapeutics Inc Stock (HOTH) Latest News
How to forecast Hoth Therapeutics Inc. trends using time seriesMarket Rally & Reliable Breakout Forecasts - newser.com
What candlestick patterns are forming on Hoth Therapeutics Inc.July 2025 Price Swings & Accurate Trade Setup Notifications - newser.com
Is Hoth Therapeutics Inc. stock entering bullish territoryJuly 2025 Institutional & Fast Gain Stock Trading Tips - newser.com
What valuation multiples suggest for Hoth Therapeutics Inc. stockMarket Movers & Fast Entry Momentum Trade Alerts - newser.com
What analysts say about Hoth Therapeutics Inc stockSector ETF Performance & Free High Yield Growth Strategies - earlytimes.in
Hoth Therapeutics shares climb after expanding AI partnership with NVIDIA - MSN
Hoth Therapeutics stock rises after expanding AI initiative with NVIDIA By Investing.com - Investing.com Nigeria
Hoth Therapeutics stock rises after expanding AI initiative with NVIDIA - Investing.com
Hoth Therapeutics rises as it expands AI push with Nvidia licenses - TradingView
Hoth Therapeutics expands artificial intelligence initiative, selects NVIDIA AI Enterprise platform - MarketScreener
Hoth Therapeutics expands AI capabilities with NVIDIA partnership - Investing.com
Hoth Therapeutics expands AI capabilities with NVIDIA partnership By Investing.com - Investing.com UK
Hoth Therapeutics Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise Platform - MarketScreener
Nov 3–5, 2025: Hoth Therapeutics CEO Robb Knie to Present on HT-001 and HT-KIT at BIO‑Europe in Vienna - Stock Titan
Analyzing Hoth Therapeutics Inc. with multi timeframe chartsVolume Spike & Community Verified Swing Trade Signals - newser.com
Best data tools to analyze Hoth Therapeutics Inc. stock2025 Analyst Calls & Low Volatility Stock Suggestions - newser.com
Hoth Therapeutics Announces Pipeline Presentation at the 2022 BIO International Convention - ADVFN
EGFR Inhibitors Induced Skin Disorders Market Research 2025-2035: Epidemiology, Regulations, Pipeline Analysis Featuring Azitra, Hoth Therapeutics, and Lutris PharmaResearchAndMarkets.com - The AI Journal
About Us - FinancialContent
Is Hoth Therapeutics Inc a good long term investmentCandlestick Pattern Analysis & Free Exceptional Risk Adjusted Gains - earlytimes.in
What institutional flow reveals about Hoth Therapeutics Inc.Portfolio Value Summary & High Yield Stock Recommendations - newser.com
EGFR Inhibitors-Induced Skin Disorders Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Lutris Pharma, Hoth Therapeutics, TWi Biotechnology - Barchart.com
Hoth expands HT-001 development with patents for cancer therapy side effects - Investing.com Nigeria
Hoth expands HT-001 development with patents for cancer therapy side effects By Investing.com - Investing.com South Africa
Hoth Therapeutics Expands Patent Portfolio for HT-001 to Target Wider Range of Skin Toxicities - MarketScreener
Hoth Therapeutics Expands HT-001 Development with Patent Filings Targeting Drug-Induced Hypersensitivity, Radiotherapy-Induced Rash, and MENIN Inhibitor-Associated Skin Toxicities - WV News
Hoth Therapeutics Expands HT-001 Development With Patent Filings Targeting Drug-Induced Hypersensitivity, Radiotherapy-Induced Rash, and MENIN Inhibitor-Associated Skin Toxicities - 富途牛牛
Hoth Therapeutics, Inc. (HOTH) Files EMA Application for Global Expansion of HT-001 Skin Therapy - Yahoo Finance
Chart Watch: Can Hoth Therapeutics Inc stock double in the next year2025 Trade Ideas & Community Verified Watchlist Alerts - خودرو بانک
Bull Run: Will Hoth Therapeutics Inc benefit from rising consumer demandMarket Performance Report & Risk Controlled Stock Pick Alerts - خودرو بانک
New Highs: Whats the MACD signal for Hoth Therapeutics IncWeekly Trend Recap & Proven Capital Preservation Tips - خودرو بانک
Risks Report: Whats the outlook for Hoth Therapeutics Incs sectorWeekly Trading Summary & Daily Price Action Insights - خودرو بانک
Market Review: Is NGVT a momentum stockMarket Weekly Review & Risk Controlled Swing Alerts - khodrobank.com
Is Hoth Therapeutics Inc benefiting from innovation trendsEarnings Recap Report & Real-Time Volume Surge Alerts - خودرو بانک
Market Outlook: Will Hoth Therapeutics Inc. announce a stock splitQuarterly Profit Summary & Advanced Swing Trade Entry Alerts - خودرو بانک
Aug Shorts: How correlated is Hoth Therapeutics Inc to the S P500July 2025 Big Picture & Expert Verified Movement Alerts - خودرو بانک
Risk Analysis: What are the future prospects of NEEPRTTrade Ideas & Real-Time Sentiment Analysis - خودرو بانک
Take Profit: Will Hoth Therapeutics Inc benefit from rising consumer demand2025 Risk Factors & High Conviction Buy Zone Picks - خودرو بانک
Risk Hedge: Is Monster Beverage Corporation a defensive stockProduct Launch & Daily Risk Controlled Trade Plans - خودرو بانک
Hoth Therapeutics issues update- HT-001, HT-KIT, VA Obesity Program drive strongest position in company history - MarketScreener
Hoth Therapeutics Issues Shareholder Update: HT-001, HT-KIT, Expanded Treasury Reserve Strategy, and VA Obesity Program Drive Strongest Position in Company History - WV News
Support Test: What is the dividend yield of Hoth Therapeutics Inc2025 Biggest Moves & Entry Point Confirmation Signals - خودرو بانک
Risk Off: What is Hoth Therapeutics Inc. s debt to equity ratioJuly 2025 Price Swings & Advanced Swing Trade Entry Plans - خودرو بانک
Hoth Therapeutics Inc Stock (HOTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):